Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Puma Biotechnology stock in Canada | $10.55
Own Puma Biotechnology shares in just a few minutes.
Puma Biotechnology is a biotechnology business based in the US. Puma Biotechnology stocks (PBYI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.08 – an increase of 6.78% over the previous week. Puma Biotechnology employs 267 staff and has a trailing 12-month revenue of around $272.1 million.
How to buy Puma Biotechnology stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: PBYI in this case.
- Research Puma Biotechnology stocks. The platform should provide the latest information available.
- Buy your Puma Biotechnology stocks. It's that simple.
What's in this guide?
- Can I buy shares in Puma Biotechnology?
- Has coronavirus impacted Puma Biotechnology shares?
- Puma Biotechnology shares summary
- Compare share dealing platforms
- Is Puma Biotechnology stock a buy or sell?
- Puma Biotechnology performance over time
- Can I short Puma Biotechnology shares?
- Are Puma Biotechnology shares over-valued?
- Puma Biotechnology's financials
- How volatile are Puma Biotechnology shares?
- Does Puma Biotechnology pay a dividend?
- Other common questions
How has Coronavirus impacted Puma Biotechnology's stock price?
Since the stock market crash in March caused by coronavirus, Puma Biotechnology's stock price has had significant negative movement.
Its last market close was $10.55, which is 22.43% down on its pre-crash value of $13.6 and 91.82% up on the lowest point reached during the March crash when the stocks fell as low as $5.5.
If you had bought $1,000 worth of Puma Biotechnology stocks at the start of February 2020, those stocks would have been worth $917.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,312.21.
Puma Biotechnology stock priceUse our graph to track the performance of PBYI stocks over time.
Puma Biotechnology stocks at a glance
|Latest market close||$10.55|
|52-week range||$7.48 - $14.14|
|50-day moving average||$9.5471|
|200-day moving average||$10.4112|
|Wall St. target price||$9.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.41|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Puma Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Puma Biotechnology price performance over time
|1 month (2021-06-28)||16.19%|
|3 months (2021-04-28)||3.43%|
Is Puma Biotechnology under- or over-valued?
Valuing Puma Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Puma Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Puma Biotechnology's PEG ratio
Puma Biotechnology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.03. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Puma Biotechnology's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Puma Biotechnology's EBITDA
Puma Biotechnology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$35.1 million.
The EBITDA is a measure of a Puma Biotechnology's overall financial performance and is widely used to measure a its profitability.
Puma Biotechnology financials
|Revenue TTM||USD$272.1 million|
|Operating margin TTM||8.82%|
|Gross profit TTM||USD$185.7 million|
|Return on assets TTM||6.2%|
|Return on equity TTM||-205.58%|
|Market capitalisation||USD$332.6 million|
TTM: trailing 12 months
How to short and sell Puma Biotechnology stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "PBYI.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 2.7 million Puma Biotechnology stocks held short by investors – that's known as Puma Biotechnology's "short interest". This figure is 28.4% down from 3.8 million last month.
There are a few different ways that this level of interest in shorting Puma Biotechnology stocks can be evaluated.
Puma Biotechnology's "short interest ratio" (SIR)
Puma Biotechnology's "short interest ratio" (SIR) is the quantity of Puma Biotechnology stocks currently shorted divided by the average quantity of Puma Biotechnology stocks traded daily (recently around 446941.12769486). Puma Biotechnology's SIR currently stands at 6.03. In other words for every 100,000 Puma Biotechnology stocks traded daily on the market, roughly 6030 stocks are currently held short.
However Puma Biotechnology's short interest can also be evaluated against the total number of Puma Biotechnology stocks, or, against the total number of tradable Puma Biotechnology stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Puma Biotechnology's short interest could be expressed as 0.07% of the outstanding stocks (for every 100,000 Puma Biotechnology stocks in existence, roughly 70 stocks are currently held short) or 0.0908% of the tradable stocks (for every 100,000 tradable Puma Biotechnology stocks, roughly 91 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Puma Biotechnology.
Find out more about how you can short Puma Biotechnology stock.
Puma Biotechnology stock dividends
We're not expecting Puma Biotechnology to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Puma Biotechnology stock price volatility
Over the last 12 months, Puma Biotechnology's stocks have ranged in value from as little as $7.48 up to $14.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Puma Biotechnology's is 1.2448. This would suggest that Puma Biotechnology's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Puma Biotechnology overview
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Stocks similar to Puma Biotechnology
Puma Biotechnology in the news
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Frequently asked questions
More guides on Finder
How to buy Zevia PBC (ZVIA) stock in Canada
Everything we know about the Zevia PBC IPO, plus information on how to buy in.
How to buy Xponential Fitness (XPOF) stock in Canada
Everything we know about the Xponential Fitness IPO, plus information on how to buy in.
How to buy SOPHiA Genetics (SOPH) stock in Canada
Everything we know about the SOPHiA Genetics IPO, plus information on how to buy in.
How to buy Ryan Specialty Group Holdings (RYAN) stock in Canada
Everything we know about the Ryan Specialty Group Holdings IPO, plus information on how to buy in.
How to buy Ocean Biomedical (OCEA) stock in Canada when it goes public
Everything we know about the Ocean Biomedical IPO, plus information on how to buy in.
How to buy Instructure Holdings (INST) stock in Canada
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
How to buy Gambling.com Group (GAMB) stock in Canada
Everything we know about the Gambling.com Group IPO, plus information on how to buy in.
How to buy Elicio Therapeutics (ELTX) stock in Canada when it goes public
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
How to buy Cytek Biosciences (CTKB) stock in Canada
Everything we know about the Cytek Biosciences IPO, plus information on how to buy in.
How to buy Core & Main (CNM) stock in Canada
Everything we know about the Core & Main IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.